Cargando…
Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma
Autores principales: | Couillard, Simon, Shrimanker, Rahul, Chaudhuri, Rekha, Mansur, Adel H., McGarvey, Lorcan P., Heaney, Liam G., Fowler, Stephen J., Bradding, Peter, Pavord, Ian D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521703/ https://www.ncbi.nlm.nih.gov/pubmed/34129808 http://dx.doi.org/10.1164/rccm.202104-1040LE |
Ejemplares similares
-
Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker‐high and ‐low severe asthma
por: Khalfaoui, Latifa, et al.
Publicado: (2022) -
Utility of fractional exhaled nitric oxide suppression as a prediction tool for progression to biologic therapy
por: Butler, Claire A., et al.
Publicado: (2021) -
Fractional exhaled nitric oxide (FeNO): the future of asthma care?
por: Wang, Kay, et al.
Publicado: (2023) -
Assessment of adherence to corticosteroids in asthma by drug monitoring or fractional exhaled nitric oxide: A literature review
por: Alahmadi, Fahad, et al.
Publicado: (2020) -
Blood eosinophils, fractional exhaled nitric oxide and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling
por: Couillard, Simon, et al.
Publicado: (2022)